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Abstract
The American College of Cardiology Foundation (ACCF),
Society for Cardiovascular Angiography and Interventions,
Society of Thoracic Surgeons, and the American Associa-
tion for Thoracic Surgery, along with key specialty and
subspecialty societies, conducted an update of the appropri-
ate use criteria (AUC) for coronary revascularization fre-
quently considered. In the initial document, 180 clinical
scenarios were developed to mimic patient presentations
encountered in everyday practice and included information
on symptom status, extent of medical therapy, risk level as
assessed by noninvasive testing, and coronary anatomy. This
update provides a reassessment of clinical scenarios the
writing group felt to be affected by significant changes in the
medical literature or gaps from prior criteria. The method-
ology used in this update is similar to the initial document,
and the definition of appropriateness was unchanged. The
technical panel scored the clinical scenarios on a scale of 1 to 9.
Scores of 7 to 9 indicate that revascularization is considered
appropriate and likely to improve patients’ health outcomes
or survival. Scores of 1 to 3 indicate revascularization is
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outcomes or survival. Scores in the mid-range (4 to 6)
indicate a clinical scenario for which the likelihood that
coronary revascularization will improve health outcomes or
survival is uncertain.
In general, as seen with the prior AUC, the use of
coronary revascularization for patients with acute coronary
syndromes and combinations of significant symptoms
and/or ischemia is appropriate. In contrast, revascularization
of asymptomatic patients or patients with low-risk findings
on noninvasive testing and minimal medical therapy are
viewed less favorably. The technical panel felt that based on
recent studies, coronary artery bypass grafting remains an
appropriate method of revascularization for patients with
high burden of coronary artery disease (CAD). Addition-
ally, percutaneous coronary intervention may have a role in
revascularization of patients with high burden of CAD. The
primary objective of the appropriate use criteria is to
improve physician decision making and patient education
regarding expected benefits from revascularization and to
guide future research.
Preface
The American College of Cardiology Foundation (ACCF),
in collaboration with the Society for Cardiovascular An-
giography and Interventions (SCAI), the Society of Tho-
racic Surgeons (STS), the American Association for Tho-
racic Surgery (AATS), and other societies, developed and
published in 2009 appropriate use criteria (AUC) for certain
clinical scenarios in which coronary revascularization could
be used in an effort to address the rational use of coronary
revascularization in the delivery of high-quality care. This
document is the first focused update of the original docu-
ment and includes new literature published since the orig-
inal document and gaps noted during implementation.
The publication of AUC reflects one of several ongoing
efforts by the ACCF and its partners to assist clinicians
caring for patients with cardiovascular diseases and in
support of high-quality cardiovascular care. The ACCF/
American Heart Association (AHA) clinical practice guide-
lines provide a foundation for summarizing evidence-based
cardiovascular care and, when evidence is lacking, provide
expert consensus opinion that is approved in review by the
ACCF and AHA. However, in many areas, variability
remains in the use of cardiovascular procedures, raising
questions of over- or underuse. The AUC provide a prac-
tical standard upon which to assess and better understand
variability.
We are grateful to the technical panel and its chair,
Frederick A. Masoudi, MD, MSPH, FACC, FAHA, a
professional group with a wide range of skills and insights,
for their thoughtful and thorough deliberation of the merits
of coronary revascularization for various clinical scenarios.
We would also like to thank the parent AUC Task Forceand the ACCF staff, Joseph M. Allen and Lea Binder, for
their exceptionally skilled support in the generation of this
document.
Manesh R. Patel, MD, FACC
Chair, Coronary Revascularization Writing Group
Michael J. Wolk, MD, MACC
Chair, Appropriate Use Criteria Task Force
Introduction
This report is a focused update of the AUC for coronary
revascularization published in 2009 (1). The increasing
prevalence of coronary artery disease (CAD), continued
advances in surgical and percutaneous techniques for revas-
cularization and concomitant medical therapy for CAD,
and the costs of revascularization have resulted in height-
ened interest regarding the appropriate use of coronary
revascularization. Clinicians, payers, and patients are inter-
ested in the specific benefits of revascularization. Inappro-
priate revascularization may be harmful to patients and
generate unwarranted costs to the healthcare system,
whereas appropriate revascularization procedures can im-
prove patients’ clinical outcomes.
As in the original AUC document, the same classification
scheme with ratings of appropriate, uncertain, and inappro-
priate was used. The uncertain category can cause confusion
in the interpretation of the AUC and can imply several
meanings within its definition. First, the rating of uncertain
is used when pertinent literature is either not available or
when true discrepancies exist. Second, it is impossible to
include every relevant piece of clinical information (e.g., age,
sex, diabetes) in the individual clinical scenarios. Attempt-
ing to do that may result in an unmanageable number of
clinical scenarios and thus compromise the usefulness of the
AUC in daily practice. The practice of medicine is full of
uncertainties that require a thoughtful clinician to use his or
her best judgment about each patient to reach decisions
about management. Therefore, a rating of uncertain may be
assigned by members of the technical panel if clinical
information not provided might affect their individual
rating, causing a shift into either the appropriate or inap-
propriate category.
A rating of uncertain means simply what the name
implies, and depending on additional factors, it can be
appropriate or inappropriate to perform revascularization.
The writing group emphasizes that uncertain indications are
not inappropriate. Rather, they reflect clinical scenarios that
are reasonable for performing revascularization, but addi-
tional clinical factors should be considered or further re-
search is needed to more definitively define the benefits of
treatment for patients.
All prior AUC publications have reflected an ongoing
effort to critically and systematically create, review, and
categorize the appropriateness of certain cardiovascular
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ization remains the only document addressing treatment.
The writing group and technical panel members for this
update are identical to the initial AUC (with only 1
exception) and comprised of members from relevant profes-
sional societies including both practicing interventional
cardiologists and a cardiothoracic surgeon.
For the majority of clinical scenarios, the technical panel
only considered the appropriate use of revascularization
irrespective of whether this was accomplished by percuta-
neous coronary intervention (PCI) or coronary artery bypass
graft surgery (CABG). However, in a select subgroup of
clinical scenarios in which revascularization is generally
considered appropriate, the appropriateness of PCI and
CABG, individually, was considered. In this subgroup, it
was recognized that a focused update could be necessary
following publication of the SYNTAX (Synergy Between
PCI With TAXUS and Cardiac Surgery) trial (2). There-
fore, in this update, the writing group identified 4 indica-
tions possibly affected by results of the SYNTAX trial for
reexamination. The writing group also split 2 of the indi-
cations to represent levels of disease burden, recognizing,
however, that the ability to reproducibly quantify the
SYNTAX score in routine clinical practice has challenges.
Also in this subgroup, the variables of diabetes and de-
pressed left ventricular function were included in the initial
AUC, but these were combined for the update because all
indications with these variables were rated the same in the
previous scores by the technical panel.
In addition, since the publication of the original docu-
ment, efforts to implement data collection protocols related
to the AUC indications identified a gap in the clinical
scenarios related to lower-risk unstable angina/non–ST-
segment elevation myocardial infarction (UA/NSTEMI)
patients and asymptomatic patients with 1- or 2-vessel
CAD not involving the proximal left anterior descending
artery (LAD) in whom no noninvasive testing had been
performed. Although limited new evidence is available
for these patient populations since publication, the writ-
ing group developed indications to address these previous
omissions.
Methods
A detailed description of the methods used for rating the
selected clinical indications is found in a previous publica-
tion, “ACCF Proposed Method for Evaluating the Appro-
priateness of Cardiovascular Imaging” (3). Briefly, this
process combines evidence-based medicine and practice
experience by engaging a technical panel in a modified
Delphi exercise. The technical panel is created from nom-
inations given by multiple relevant professional societies and
provider-led organizations as well as from health policy and
payer communities. To preserve objectivity, technical panelsare created so as to not include a majority of individuals
whose livelihood is tied to the technology under evaluation.
In making its appropriate use determinations, the tech-
nical panel is provided with summaries of the relevant
evidence from the medical literature and practice guidelines.
Panelists are first asked individually, and then collectively, to
assess the benefits and risks of a test or procedure in the
context of the potential benefits to patients’ outcomes and
an implicit understanding of the associated resource use and
costs. After the rating process, the final appropriate use
ratings are summarized using an established rigorous meth-
odology (4).
Indication Development
Appropriate use criteria are based on current understanding
of the technical capabilities and potential patient benefits of
the procedures examined. The AUC are also developed to
identify common clinical scenarios—but they cannot pos-
sibly include every conceivable patient presentation. The
term indication is used interchangeably with clinical scenario
n the document for brevity and does not imply that a
rocedure should necessarily be performed. Some patients
een in clinical practice are not represented in these appro-
riate use criteria or have additional extenuating features
hat would alter the appropriateness of treatment as compared
ith the clinical scenarios presented. Additionally, although
UC indications and ratings are shaped by the guidelines, the
UC often contain more detailed clinical scenarios than the
ore generalized situations covered in clinical practice guide-
ines, and thus, subtle differences between these 2 guidance
ools may be possible. To minimize this possibility, the
oronary revascularization criteria were updated in conjunction
ith members of the ACCF/AHA PCI and CABG revascu-
arization guideline committees.
Appropriate use criteria are intended to assist patients
nd clinicians, but are not intended to diminish the ac-
nowledged difficulty or uncertainty of clinical decision
aking and cannot act as substitutes for sound clinical
udgment and practice experience. Rather, the aim of these
riteria is to allow assessment of utilization patterns for a test or
rocedure. Comparing utilization patterns across a large subset
f provider’s patients can allow for an assessment of a provider’s
anagement strategies with those of his/her peers. The ACCF
nd its collaborators believe that an ongoing review of one’s
ractice using these criteria will help guide a more effective,
fficient, and equitable allocation of healthcare resources, and
ltimately, better patient outcomes.
The indications went through external review by multi-
ociety and specialty representation for the 2009 document.
ecause of the narrow focus, the indications were not sent
or external review for this update.
Scope of Indications
As previously described, the indications for coronary revas-
cularization were developed considering the following com-
mon variables:
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stable angina);
b. Severity of angina (asymptomatic, Canadian Cardiovas-
cular Society [CCS] Class I, II, III, or IV);
c. Extent of ischemia on noninvasive testing and the
presence or absence of other prognostic factors, such as
congestive heart failure, depressed left ventricular func-
tion, or diabetes;
d. Extent of medical therapy; and
e. Extent of anatomic disease (1-, 2-, 3-vessel disease, with
or without proximal LAD or left main coronary disease).
The clinical scenarios developed include coronary anat-
omy, as this is the focus of much of the previous literature on
coronary revascularization. However, the writing group recog-
nizes that for everyday patient care, symptom status, ischemic
burden, and level of medical therapy often play a critical role in
decision making even before the coronary anatomy has been
defined by angiography. It is important to note that the
indications focus on revascularization, percutaneous or surgical,
and do not address diagnostic catheterization or coronary
angiography; these criteria are currently under development.
Technical Panel Selection
Stakeholders were given the opportunity to participate in
the AUC process by submitting nominees from their
organizations through a call for nominations announced in
the summer of 2006. From this list of nominees, the AUC
Task Force and writing group selected technical panel
members to ensure an appropriate balance with respect to
expertise. The 17-member technical panel was composed of 4
interventional cardiologists, 4 cardiovascular surgeons, 8 mem-
bers representing noninterventional cardiologists, other physi-
cians who treat patients with cardiovascular disease, health
outcome researchers, and 1 medical officer from a health plan.
For the update of the AUC for coronary revascularization, the
same technical panelists (with 1 exception) from the original
document published in 2009 were reconvened to rerate the 15
clinical scenarios included in the focused update.
Rating Process and Scoring
The technical panel members first rated indications inde-
pendently. Then, the technical panel participated in 2
conferences calls for a discussion of each indication. After
the discussion, panelists independently provided their final
scores for each indication. Each panelist had equal weight in
producing the final result for the indications and was not
forced into consensus. For each indication, the median
numerical score was determined and then assigned to an
appropriate use category.
For the conference calls, each technical panelist received
a personalized rating form that indicated his/her rating for
each indication and the distribution of de-identified ratings
of other members of the panel. In addition, the moderator
received a summary rating form with similar information
(including panelist identification), along with other statistics
reflecting the level of agreement among technical panelmembers. The level of agreement among panelists, as
defined by RAND, was analyzed for each indication based
on the BIOMED rule for a panel of 14 to 16 (a simplified
RAND method for determining disagreement) (4). Per the
BIOMED definition, agreement was defined as an indica-
tion where 4 or fewer panelists’ ratings fell outside the 3-point
region containing the median score. Disagreement was defined
as a situation where at least 5 panelists’ ratings fell in both the
appropriate and the inappropriate categories. Because the
technical panel had 17 representatives, which exceeded the 16
addressed in this rule, an additional level of agreement analysis
as described by RAND was performed that examined the
interpercentile range compared with interpercentile range ad-
justed for symmetry (4). This information was used by the
moderator to guide the technical panel’s discussion by high-
lighting areas of differences among the panelists.
In developing these appropriate use criteria for coronary
revascularization, the technical panel was asked to assess
whether coronary revascularization for each indication was
appropriate, uncertain, or inappropriate using the following
definition of appropriate use:
Coronary revascularization is appropriate when the ex-
pected benefits, in terms of survival or health outcomes
(symptoms, functional status, and/or quality of life) exceed
the expected negative consequences of the procedure.
The technical panel scored each indication on a scale
from 1 to 9 as follows:
Median Score 7 to 9
Appropriate procedure for specific indication
(procedure is generally acceptable and is a rea-
sonable approach for the indication).
Median Score 4 to 6
Uncertain for specific indication (procedure may
be generally acceptable and may be a reasonable
approach for the indication). Uncertainty implies
that more research and/or patient information is
needed to classify the indication definitively.
Median Score 1 to 3
Inappropriate procedure for that indication (pro-
cedure is not generally acceptable and is not a
reasonable approach for the indication).
The division of these scores into 3 levels of appropriateness
is somewhat arbitrary, and the numeric designations should
be viewed as a continuum. Further, there is diversity in
clinical opinion for particular clinical scenarios, such that
scores in the intermediate level of appropriateness should be
labeled uncertain, because critical patient or research data
may be lacking or discordant. This designation serves as a
prompt to the field to carry out definitive research investi-
gations whenever possible. It is anticipated that the AUC
reports will continue to be revised as further data are
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criteria is accumulated.
To prevent bias in the scoring process, care was taken in
providing objective, nonbiased information, including
guidelines and key references, to the technical panel.
General Assumptions
Specific assumptions are provided that were considered by
the technical panel in rating the relevant clinical scenarios
for the appropriate use of revascularization:
1. Each clinical scenario includes the patient’s clinical
status/symptom complex, ischemic burden by noninva-
sive functional testing when presented, burden of cor-
onary atherosclerosis as determined by angiography,
and intensity of medical therapy in the determination of
the appropriate use of coronary revascularization.
2. Assume coronary angiography has been performed
when these findings are presented in the indications.
The technical panel should rate the appropriateness of
revascularization based upon the clinical features and
coronary findings, and not the appropriateness of diag-
nostic coronary angiography.
3. Assume left main coronary artery stenosis (greater than
or equal to 50% luminal diameter narrowing) or prox-
imal LAD stenosis (greater than or equal to 70%
luminal diameter narrowing) is not present unless
specifically noted. Assume no other significant coronary
artery stenoses are present except those noted in the
clinical scenario.
4. The clinical scenarios should be rated based on the
published literature regarding the risks and benefits of
percutaneous and surgical coronary revascularization.
Note that specific patient groups not well represented in
the literature are not presented in the current clinical
scenarios. However, the writing group recognizes that
decisions about coronary artery revascularization in
such patients are frequently required. Examples of such
patients include those with end-stage renal disease or
advanced age.
5. Clinical outcome is related to the extent of coronary
artery disease (Table A1) (5). Based on this observation
and clinical guideline recommendations regarding “bor-
derline” angiographic stenosis (50% to 60%) in epicar-
dial (non-left main) locations, a significant coronary
stenosis for the purpose of the clinical scenarios is
defined as:
X Greater than or equal to 70% luminal diameter
narrowing, by visual assessment, of an epicardial
stenosis measured in the “worst view” angiographic
projection.
X Greater than or equal to 50% luminal diameter
narrowing, by visual assessment, of a left main
stenosis measured in the “worst view” angiographic
projection.6. All patients are receiving standard care, including
guideline-based risk factor modification for primary or
secondary prevention in cardiovascular patients unless
specifically noted (6–10).
7. Despite the best efforts of the clinician, all patients may
not achieve target goals for risk factor modification.
However, a plan of care to address risk factors is
assumed to be occurring in patients represented in the
indications. For patients with chronic stable angina, the
writing group recognizes that there is a wide variance in
the medical therapy for angina. The specific definition
of maximal anti-ischemic medical therapy is presented
in the definition section and includes the use of 2 or
more antianginal medications.
8. Operators performing percutaneous or surgical revascu-
larization have appropriate clinical training and experi-
ence and have satisfactory outcomes as assessed by
quality assurance monitoring (11–13).
9. Revascularization by either percutaneous or surgical
methods is performed in a manner consistent with
established standards of care (11–13).
10. In the clinical scenarios, no unusual extenuating cir-
cumstances exist (such as inability to comply with
antiplatelet agents, do not resuscitate status, patient
unwilling to consider revascularization, technically not
feasible to perform revascularization, or comorbidities
likely to markedly increase procedural risk substantially)
unless specifically noted.
Definitions
A complete set of definitions of terms used throughout the
clinical scenarios is listed in Appendix A. These definitions
were provided to and discussed with the technical panel
Table A1. CAD Prognostic Index
Extent of CAD
Prognostic
Weight (0–100)
5-Year
Survival Rate (%)*
1-vessel disease, 75% 23 93
1-vessel disease, 50% to 74% 23 93
1-vessel disease, 95% 32 91
2-vessel disease 37 88
2-vessel disease, both 95% 42 86
1-vessel disease, 95% proximal LAD 48 83
2-vessel disease, 95% LAD 48 83
2-vessel disease, 95% proximal LAD 56 79
3-vessel disease 56 79
3-vessel disease, 95% in at least 1 63 73
3-vessel disease, 75% proximal LAD 67 67
3-vessel disease, 95% proximal LAD 74 59
*Assuming medical treatment only. Reprinted with permission from Califf et al. (5).
CAD  coronary artery disease; LAD  left anterior descending coronary artery.prior to the rating of indications.
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As previously stated, the indications assume that patients
are receiving risk factor modification according to guideline-
based recommendations. For the purposes of the clinical
scenarios presented, maximal antianginal medical therapy
is defined as the use of at least 2 classes of therapies to
reduce anginal symptoms.
Stress Testing and Risk of Findings
on Noninvasive Testing
Stress testing is commonly used for both diagnosis and risk
stratification of patients with coronary artery disease. Using
criteria defined for traditional exercise stress tests (14):
Low-risk stress test findings: associated with a cardiac
mortality of less than 1% per year
Intermediate-risk stress test findings: associated with a
1% to 3% per year cardiac mortality
High-risk stress test findings: associated with a greater
than 3% per year cardiac mortality
Examples of findings from noninvasive studies and their
ssociated level of risk for cardiac mortality are presented in
able A2 (13). As noted in the footnote to this table, for
ertain low-risk findings, there may be additional findings
hat alter the assessment of risk, but these relationships have
ot been well studied. Implicit in these risk definitions is a
easure of the amount of myocardium at risk, or ischemic
yocardium. For the purpose of the indications for coro-
ary revascularization, stress test findings are presented by
hese risk criteria. For patients without stress test findings,
lease refer to the note below on invasive methods of
etermining hemodynamic significance. Assume that when
rior testing (including an imaging procedure) is referenced
n an indication, the testing was performed correctly and
ith sufficient quality so as to produce a meaningful and
ccurate result within the limits of the test performance.
For the purposes of the clinical scenarios in this docu-
ent, patients with both typical and atypical angina are
lassified by the feature of the CCS grading system pre-
ented below. Patients with noncardiac chest pain should be
onsidered to be asymptomatic.
rading of Angina Pectoris by the Canadian
ardiovascular Society Classification System (15)
Class I: Ordinary physical activity does not cause angina,
such as walking, climbing stairs. Angina occurs with
strenuous, rapid, or prolonged exertion at work or
recreation.
Class II: Slight limitation of ordinary activity. Angina
occurs on walking more than 2 blocks on the level and
climbing more than 1 flight of ordinary stairs at a
normal pace and in normal condition.
Class III: Marked limitations of ordinary physical activ-
ity. Angina occurs on walking 1 or 2 blocks on thelevel and climbing 1 flight of stairs in normal condi-
tions and at a normal pace.
Class IV: Inability to carry on any physical activity
without discomfort—anginal symptoms may be pres-
ent at rest.
High-Risk Features for Short-Term Risk of Death or
Nonfatal MI for UA/NSTEMI (16)
At least 1 of the following:
• History—accelerating tempo of ischemic symptoms in
preceding 48 hours
• Character of pain—prolonged ongoing (greater than
20 minutes) rest pain
• Clinical findings
X Pulmonary edema, most likely due to ischemia
X New or worsening mitral regurgitation murmur
X S3 or new/worsening rales
X Hypotension, bradycardia, tachycardia
X Age greater than 75 years
• Electrocardiogram
X Angina at rest with transient ST-segment changes
greater than 0.5 mm
X Bundle-branch block, new or presumed new
X Sustained ventricular tachycardia
• Cardiac marker
X Elevated cardiac TnT, TnI, or CK-MB (e.g., TnT
or TnI greater than 0.1 ng per mL)
IMI Risk Score—for Patients With Suspected ACS (17)
ariables (1 point each)
• Age 65 years
• 3 risk factors (hypertension, diabetes mellitus, family
history, lipids, smoking)
• Known CAD (stenosis 50%)
• Aspirin use in past 7 days
• Severe angina (2 episodes within 24 hours)
• ST-segment deviation 0.5 mm
• Elevated cardiac markers
Risk of death or ischemic event through 14 days
• Low: 0–2 (8.3% event rate)
• Intermediate: 3–4 (19.3% event rate)
• High: 5–7 (41% event rate)
Abbreviations
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CCS  Canadian Cardiovascular Society
CTO  chronic total occlusion
FFR  fractional flow reserve
HF  heart failure
d
i
m
f
c
c
r
Thromb
864 Patel et al. JACC Vol. 59, No. 9, 2012
Appropriate Use Criteria for Coronary Revascularization Focused Update February 28, 2012:857–81IVUS  intravascular ultrasound
LAD  left anterior descending artery
LIMA  left internal mammary artery
LV  left ventricular
LVEF  left ventricular ejection fraction
MI  myocardial infarction
PCI  percutaneous coronary intervention
STEMI  ST-segment elevation myocardial infarction
TIMI  Thrombolysis In Myocardial Infarction
UA/NSTEMI  unstable angina/non–ST-segment
elevation myocardial infarction
Results of Updated Ratings
The writing group evaluated the previous 180 clinical
scenarios and identified those where reevaluation, expan-
Table A. Focused Update: New or Revised Indications
Indication
Patients With Acu
9. ● UA/NSTEMI and low-risk features (e.g., TIMI score 2) for sh
● Revascularization of the presumed culprit artery
10. ● UA/NSTEMI and intermediate-risk features (e.g., TIMI score 3
● Revascularization of the presumed culprit artery
Patients Without
Asym
20. ● One- or 2-vessel CAD without involvement of proximal LAD
● No noninvasive testing performed
Method of Revascularization: Multivessel CA
and/or Evidence of Intermediate- to
62. ● Two-vessel CAD with proximal LAD stenosis
63. ● Three-vessel CAD with low CAD burden (i.e., 3 focal stenoses
64. ● Three-vessel CAD with intermediate to high CAD burden (i.e.,
or high SYNTAX score)
65. ● Isolated left main stenosis
66. ● Left main stenosis and additional CAD with low CAD burden
low SYNTAX score)
67. ● Left main stenosis and additional CAD with intermediate to h
presence of CTO, or high SYNTAX score)
A  appropriate; CAD  coronary artery disease; CCS  Canadian Cardiovascular Society; CT
myocardial infarction; SYNTAX  Synergy Between PCI With TAXUS and Cardiac Surgery; TIMI 
elevation myocardial infarction.sion, or consolidation was felt necessary (Table A). Nine dof the 15 updated indications met the definition of
agreement as described above. There were no ratings
where the technical panel held such opposing viewpoints
that the technical panel’s votes were determined to be in
“disagreement” as defined by the strict RAND definitions
and described previously in the Methods section.
As the majority of the original clinical scenarios and
ratings were not rerated in this update, Table A represents
the focused update indications. In addition, the entire list of
171 clinical scenarios and their appropriateness scores are
shown below in Tables 1, 2, 3, and 4. Figures 1, 2, 3, 4, and 5
emonstrate gradients in appropriate use rating by increas-
ngly severe symptom status and ischemic risk, and by the
ethod of revascularization. These are also presented in a
ormat similar to the original document. In addition to the
hanges reflected in Table A, the fractional flow reserve (FFR)
ut point was updated from 0.75 to 0.80 in indication 22 to
eflect new literature since the publication of the original
Appropriate Use Score
(1–9)
ronary Syndromes
m risk of death or nonfatal MI U (6)
r short-term risk of death or nonfatal MI A (8)
Bypass Surgery
atic
I (3)
S Angina Greater Than or Equal to Class III,
isk Findings on Noninvasive Testing
PCI CABG
A (7) A (8)
YNTAX score) A (7) A (9)
ple diffuse lesions, presence of CTO, U (4) A (9)
U (6) A (9)
- to 2-vessel additional involvement, U (5) A (9)
AD burden (i.e., 3-vessel involvement, I (3) A (9)
ronic total occlusion; I  inappropriate; LAD  left anterior descending coronary artery; MI 
olysis In Myocardial Infarction; U  uncertain; UA/NSTEMI  unstable angina/non–ST-segmentte Co
ort-ter
–4) fo
Prior
ptom
D, CC
High-R
, low S
multi
(i.e., 1
igh C
O  chocument and to maintain consistency with guidelines (18).
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Table 1. Patients With Acute Coronary Syndromes
Indication
Appropriate Use
Score (1–9)
1. ● STEMI
● Less than or equal to 12 hours from onset of symptoms
● Revascularization of the culprit artery
A (9)
2. ● STEMI
● Onset of symptoms within the prior 12 to 24 hours
● Severe HF, persistent ischemic symptoms, or hemodynamic or electrical instability present
A (9)
3. ● STEMI
● Greater than 12 hours from symptom onset
● Asymptomatic; no hemodynamic instability and no electrical instability
I (3)
4. ● STEMI with presumed successful treatment with fibrinolysis
● Evidence of HF, recurrent ischemia, or unstable ventricular arrhythmias present
● One-vessel CAD presumed to be the culprit artery
A (9)
5. ● STEMI with presumed successful treatment with fibrinolysis
● Asymptomatic; no HF or no recurrent ischemic symptoms, or no unstable ventricular arrhythmias
● Normal LVEF
● One-vessel CAD presumed to be the culprit artery
U (5)
6. ● STEMI with presumed successful treatment with fibrinolysis
● Asymptomatic; no HF, no recurrent ischemic symptoms, or no unstable ventricular arrhythmias at time of presentation
● Depressed LVEF
● Three-vessel CAD
● Elective/semielective revascularization
A (8)
7. ● STEMI with successful treatment of the culprit artery by primary PCI or fibrinolysis
● Asymptomatic; no HF, no evidence of recurrent or provokable ischemia, or no unstable ventricular arrhythmias during
index hospitalization
● Normal LVEF
● Revascularization of a non-infarct-related artery during index hospitalization
I (2)
8. ● STEMI or NSTEMI and successful PCI of culprit artery during index hospitalization
● Symptoms of recurrent myocardial ischemia and/or high-risk findings on noninvasive stress testing performed after
index hospitalization
● Revascularization of 1 additional coronary arteries
A (8)
9. ● UA/NSTEMI and low-risk features (e.g., TIMI score 2) for short-term risk of death or nonfatal MI
● Revascularization of the presumed culprit artery
U (6)
10. ● UA/NSTEMI and intermediate-risk features (e.g., TIMI score 3–4) for short-term risk of death or nonfatal MI
● Revascularization of the presumed culprit artery
A (8)
11. ● UA/NSTEMI and high-risk features for short-term risk of death or nonfatal MI
● Revascularization of the presumed culprit artery
A (9)
12. ● UA/NSTEMI and high-risk features for short-term risk of death or nonfatal MI
● Revascularization of multiple coronary arteries when the culprit artery cannot clearly be determined
A (9)
13. ● Patients with acute myocardial infarction (STEMI or NSTEMI)
● Evidence of cardiogenic shock
● Revascularization of 1 coronary arteries
A (8)
New and updated indications are shaded blue.
A  appropriate; CAD  coronary artery disease; HF  heart failure; I  inappropriate; LVEF  left ventricular ejection fraction; MI  myocardial infarction; NSTEMI  non–ST-segment elevation
myocardial infarction; PCI percutaneous coronary intervention; STEMIST-segment elevation myocardial infarction; TIMI Thrombolysis In Myocardial Infarction; U uncertain; UA unstable angina.
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Indication Appropriate Use Score (1–9)
CCS Angina Class Asymptomatic I or II III or IV
14. ● One- or 2-vessel CAD without involvement of proximal LAD
● Low-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
I (1) I (2) U (5)
15. ● One- or 2-vessel CAD without involvement of proximal LAD
● Low-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
I (2) U (5) A (7)
16. ● One- or 2-vessel CAD without involvement of proximal LAD
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
I (3) U (5) U (6)
17. ● One- or 2-vessel CAD without involvement of proximal LAD
● Intermediate-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
U (4) A (7) A (8)
18. ● One- or 2-vessel CAD without involvement of proximal LAD
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
U (6) A (7) A (8)
19. ● One- or 2-vessel CAD without involvement of proximal LAD
● High-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
A (7) A (8) A (9)
20. ● One- or 2-vessel CAD without involvement of proximal LAD
● No noninvasive testing performed
I (3) U (5) A (7)
21. ● One- or 2-vessel CAD with borderline stenosis “50% to 60%”
● No noninvasive testing performed
● No further invasive evaluation performed (i.e., FFR, IVUS)
Not rated I (2) I (3)
22. ● One- or 2-vessel CAD with borderline stenosis “50% to 60%”
● No noninvasive testing performed or equivocal test results present
● FFR less than or equal to 0.80* and/or IVUS with significant reduction in
cross-sectional area
I (3) U (6) A (7)
23. ● One- or 2-vessel CAD with borderline stenosis “50% to 60%”
● No noninvasive testing performed or equivocal test results present
● FFR or IVUS findings do not meet criteria for significant stenosis
I (1) I (2) I (2)
24. ● Chronic total occlusion of 1 major epicardial coronary artery, without other
coronary stenoses
● Low-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
I (1) I (2) I (3)
25. ● Chronic total occlusion of 1 major epicardial coronary artery, without other
coronary stenoses
● Low-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
I (1) U (4) U (6)
26. ● Chronic total occlusion of 1 major epicardial coronary artery, without other
coronary stenoses
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
I (3) U (4) U (6)
27. ● Chronic total occlusion of 1 major epicardial coronary artery, without other
coronary stenoses
● Intermediate-risk criteria on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
U (4) U (5) A (7)
28. ● Chronic total occlusion of 1 major epicardial coronary artery, without other
coronary stenoses
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
U (4) U (5) A (7)
29. ● Chronic total occlusion of 1 major epicardial coronary artery, without other
coronary stenoses
● High-risk criteria on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
U (5) A (7) A (8)
30. ● One-vessel CAD involving the proximal LAD
● Low-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
U (4) U (5) A (7)Continued on next page
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Indication Appropriate Use Score (1–9)
CCS Angina Class Asymptomatic I or II III or IV
31. ● One-vessel CAD involving the proximal LAD
● Low-risk findings on noninvasive testing
● Receiving maximal anti-ischemic medical therapy
U (4) A (7) A (8)
32. ● One-vessel CAD involving the proximal LAD
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
U (4) U (6) A (7)
33. ● One-vessel CAD involving the proximal LAD
● Intermediate-risk findings on noninvasive testing
● Receiving maximal anti-ischemic medical therapy
U (5) A (8) A (9)
34. ● One-vessel CAD involving the proximal LAD
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
A (7) A (8) A (9)
35. ● One-vessel CAD involving the proximal LAD
● High-risk findings on noninvasive testing
● Receiving maximal anti-ischemic medical therapy
A (7) A (9) A (9)
36. ● Two-vessel CAD involving the proximal LAD
● Low-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
U (4) U (6) A (7)
37. ● Two-vessel CAD involving the proximal LAD
● Low-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
U (5) A (7) A (8)
38. ● Two-vessel CAD involving the proximal LAD
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
U (5) A (7) A (8)
39. ● Two-vessel CAD involving the proximal LAD
● Intermediate-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
U (6) A (7) A (9)
40. ● Two-vessel CAD involving the proximal LAD
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
A (7) A (8) A (9)
41. ● Two-vessel CAD involving the proximal LAD
● High-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
A (8) A (9) A (9)
42. ● Three-vessel CAD (no left main)
● Low-risk findings on noninvasive testing including normal
LV systolic function
● Receiving no or minimal anti-ischemic medical therapy
U (5) U (6) A (7)
43. ● Three-vessel CAD (no left main)
● Low-risk findings on noninvasive testing including normal
LV systolic function
● Receiving a course of maximal anti-ischemic medical therapy
U (5) A (7) A (8)
44. ● Three-vessel CAD (no left main)
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
A (7) A (7) A (8)
45. ● Three-vessel CAD (no left main)
● Intermediate-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
A (7) A (8) A (9)
46. ● Three-vessel CAD (no left main)
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
A (7) A (8) A (9)
47. ● Three-vessel CAD (no left main)
● High-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
A (8) A (9) A (9)
48. ● Three-vessel CAD (no left main)
● Abnormal LV systolic function
A (8) A (9) A (9)
49. ● Left main stenosis A (9) A (9) A (9)
New and updated indications are shaded blue. *FFR cut point updated from 0.75 to 0.80 to reflect new literature since publication of the original document and to maintain consistency with guidelines (18).
A appropriate; CAD coronary artery disease; CCS Canadian Cardiovascular Society; I inappropriate; LAD left anterior descending coronary artery; LV left ventricular; LVEF left ventricular
ejection fraction; U  uncertain.
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Indication Appropriate Use Score (1–9)
CCS Angina Class Asymptomatic I or II III or IV
50. ● One or more stenoses in saphenous vein graft(s)
● Low-risk findings on noninvasive testing including normal LV systolic function
● Receiving no or minimal anti-ischemic medical therapy
I (3) U (4) U (6)
51. ● One or more stenoses in saphenous vein graft(s)
● Low-risk findings on noninvasive testing including normal LV systolic function
● Receiving a course of maximal anti-ischemic medical therapy
U (4) U (6) A (7)
52. ● One or more stenoses in saphenous vein graft(s)
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
U (4) U (6) A (7)
53. ● One or more stenoses in saphenous vein graft(s)
● Intermediate-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
U (4) A (7) A (8)
54. ● One or more stenoses in saphenous vein graft(s)
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
U (6) A (7) A (7)
55. ● One or more stenoses in saphenous vein graft(s)
● High-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
A (7) A (8) A (9)
56. ● One or more lesions in native coronary arteries without bypass grafts
● All bypass grafts patent and without significant disease
● Low-risk findings on noninvasive testing including normal LV systolic function
● Receiving no or minimal anti-ischemic medical therapy
Not rated I (3) U (6)
57. ● One or more lesions in native coronary arteries without bypass grafts
● All bypass grafts patent and without significant disease
● Low-risk findings on noninvasive testing including normal LV systolic function
● Receiving a course of maximal anti-ischemic medical therapy
I (3) U (5) A (7)
58. ● One or more lesions in native coronary arteries without bypass grafts
● All bypass grafts patent and without significant disease
● Intermediate-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
I (3) U (5) A (7)
59. ● One or more lesions in native coronary arteries without bypass grafts
● All bypass grafts patent and without significant disease
● Intermediate-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
U (4) U (6) A (8)
60. ● One or more lesions in native coronary arteries without bypass grafts
● All bypass grafts patent and without significant disease
● High-risk findings on noninvasive testing
● Receiving no or minimal anti-ischemic medical therapy
U (6) A (7) A (8)
61. ● One or more lesions in native coronary arteries without bypass grafts
● All bypass grafts patent and without significant disease
● High-risk findings on noninvasive testing
● Receiving a course of maximal anti-ischemic medical therapy
U (5) A (8) A (9)A  appropriate; CCS  Canadian Cardiovascular Society; I  inappropriate; LV  left ventricular; U  uncertain.
fdescending coronary artery; LIMA  left internal mammary artery; LVEF  left ventricular ejection fraction; PCI  percutaneous coronary intervention; SYNTAX  Synergy Between PCI With TAXUS and
Cardiac Surgery; U  uncertain.
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*The fact that the use of coronary revascularization for a particular condition is listed in this figure (appropriate, uncertain, inappropriate) does not preclude the use of other
therapeutic modalities that may be equally effective. See the most current ACCF/AHA UA/NSTEMI and STEMI guidelines (16,23). A  appropriate; CAD  coronary artery dis-Table 4. Method of Revascularization: Multivessel CAD, CCS Angina Greater Than or Equal to Class III, and/or Evidence of
Intermediate- to High-Risk Findings on Noninvasive Testing*
Indication
Appropriate
Use Score (1–9)
PCI CABG
62. ● Two-vessel CAD with proximal LAD stenosis A (7) A (8)
63. ● Three-vessel CAD with low CAD burden (i.e., 3 focal stenoses, low SYNTAX score) A (7) A (9)
64. ● Three-vessel CAD with intermediate to high CAD burden (i.e., multiple diffuse lesions, presence of CTO, or
high SYNTAX score)
U (4) A (9)
65. ● Isolated left main stenosis U (6) A (9)
66. ● Left main stenosis and additional CAD with low CAD burden (i.e., 1- to 2-vessel additional involvement, low
SYNTAX score)
U (5) A (9)
67. ● Left main stenosis and additional CAD with intermediate to high CAD burden (i.e., 3-vessel involvement,
presence of CTO, or high SYNTAX score)
I (3) A (9)
68. ● Prior bypass surgery with native 3-vessel disease and failure of multiple bypass grafts
● LIMA remains patent to a native coronary artery
● Depressed LVEF
U (6) A (7)
69. ● Prior bypass surgery with native 3-vessel disease and failure of multiple bypass grafts
● LIMA was used as a graft but is no longer functional
● Depressed LVEF
A (8) U (6)
New and updated indications are shaded blue. *The 2009 appropriate use criteria (1) separated out diabetes and normal or depressed LVEF for the indications in this table, but they were combined
or the focused update because these clinical variables did not affect the ratings.
A  appropriate; CABG  coronary artery bypass graft; CAD  coronary artery disease; CCS  Canadian Cardiovascular Society; CTO  chronic total occlusion; I  inappropriate; LAD  left anteriorease; HF  heart failure; I  inappropriate; LVEF  left ventricular ejection fraction; PCI  percutaneous coronary intervention; STEMI  ST-elevation myocardial infarction;
U  uncertain; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction.
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(Patients Without Prior Bypass Surgery)
A  appropriate; CTO  chronic total occlusion; I  inappropriate; Int.  intermediate; Max  maximum; min  minimal; Med.  medical; prox. LAD  proximal left anterior
descending artery; Rx  treatment; U  uncertain; vz.  vessel.Figure 3. Appropriate Use Ratings by Intermediate-Risk Findings on Noninvasive Imaging Study and CCS Class I or II Angina
(Patients Without Prior Bypass Surgery)
A  appropriate; CCS  Canadian Cardiovascular Society; CTO  chronic total occlusion; I  inappropriate; Int.  intermediate; Max  maximum; min  minimal; Med. 
medical; prox. LAD  proximal left anterior descending artery; Rx  treatment; U  uncertain; vz.  vessel.
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(Patients Without Prior Bypass Surgery)
A  appropriate; CCS  Canadian Cardiovascular Society; CTO  chronic total occlusion; I  inappropriate; Int.  intermediate; Max  maximum; min  minimal; Med. 
medical; prox. LAD  proximal left anterior descending artery; Rx  treatment; U  uncertain; vz.  vessel.Figure 5. Method of Revascularization of Multivessel Coronary Artery DiseaseA  appropriate; CABG  coronary artery bypass grafting; CAD  coronary artery disease; CTO  chronic total occlusion; I  inappropriate; LAD  left anterior descending
artery; PCI  percutaneous coronary intervention; SYNTAX  Synergy Between PCI With TAXUS and Cardiac Surgery; U  uncertain.
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Mode of Revascularization (Indications 62 to 69)
Recognizing that variability in revascularization methods
is often based upon patient factors and local practice
patterns, the majority of indications are not intended to
distinguish between the specific modes of revasculariza-
tion (i.e., PCI vs. CABG). However, the writing group
recognized that among patients with extensive or com-
plex atherosclerosis, the mode of revascularization is also
of interest when revascularization is deemed appropriate.
Therefore, Table 4 presents clinical scenarios where the
technical panelists were asked to consider the appropriate
use of PCI and CABG as the revascularization method
independently of each other (such that each modality
would receive separate scores based on each specific
clinical indication). These ratings are not intended to be
a competitive ranking of PCI versus CABG, or to
prioritize a specific approach when both are rated to have
the same level of appropriateness.
Many of the known clinical factors that increase the risk of
revascularization are shared between CABG and percutaneous
methods. In the original AUC for revascularization, clinical
scenarios were developed that included diabetes and LV
function to stratify patients, but when rated, these features did
not result in different ratings and thus were not used in this
focused update. However, in an attempt to further stratify
patients, the SYNTAX score is used in some of the new
clinical scenarios.
The clinical scenarios below specifically apply to patients
with multivessel CAD. It is assumed for these clinical
scenarios that all patients have unacceptable levels of symp-
toms despite appropriate medical therapy and evidence of
intermediate- to high-risk findings on noninvasive testing.
In other words, the technical panel assumed that revascu-
larization is appropriate and focused on rating the merit of
the different modes with the intent of complete coronary
revascularization for each indication.
In addition, it is assumed that no unusual extenuating
circumstances exist (inability to comply with antiplatelet
agents, patient is do not resuscitate status, patient pref-
erence strongly favoring 1 therapy or comorbidities likely
to markedly increase procedural risk substantially). As
such, the technical panel rated the appropriateness of
PCI and CABG based on the information in the indica-
tion alone, assuming other variables are not present that
would impact the decision.
Discussion
The ultimate objective of AUC is to improve patient care
and health outcomes. The ACCF and its collaborators
believe that careful blending of a broad range of clinical
experiences and available evidence-based information will
help guide a more efficient and equitable allocation ofhealthcare resources in cardiovascular revascularization.
This approach is not intended to diminish the acknowl-
edged difficulty or uncertainty of clinical decision mak-
ing. Appropriate use criteria are not substitutes for sound
clinical judgment and practice experience. It is acknowl-
edged that some patients seen in clinical practice may not
be represented in the AUC or have extenuating features
when compared with the clinical scenarios presented.
Since the publication of the original coronary revasculariza-
tion AUC, there has been substantial national focus on the
variability and appropriateness of coronary revascularization.
The 2009 AUC specifically for coronary revascularization by
PCI has been mapped to the National Cardiovascular Data,
Registry (NCDR) CathPCI registry data, and each institu-
tion’s benchmarked results are now provided to member
facilities in quarterly reports as a test quality metric. This initial
assessment of PCI appropriateness within the NCDR data was
also published by Chan and colleagues (19). Hospitals and
operators are encouraged to review their specific reports as
part of a quality improvement program to ensure data
accuracy and increase the use of appropriate revascular-
ization. Additionally, the SYNTAX trial, which was not
formally published until 2009, was anticipated to possibly
have an impact on the AUC. Despite calls for earlier
updates of specific clinical scenarios, such as the isolated
left main coronary artery revascularization, the writing
group awaited the peer-reviewed publication of both the
original trial data and the intermediate-term follow-up.
This focused update highlights 2 specific areas that were
felt to require reconsideration: 1) specific indications that
represent gaps identified when mapping the 2009 AUC to
the CathPCI registry; and 2) re-evaluation of the indica-
tions for the treatment of multivessel CAD with symptoms
by method (PCI and CABG) of revascularization as a result
of data from the SYNTAX trial.
New Clinical Scenarios to Address Gaps
The 2009 AUC document only had 1 clinical scenario for
UA/NSTEMI and high-risk features, which was graded as
appropriate. The ratings for these new clinical scenarios
(Indications 9 and 10) focus on patients with UA/NSTEMI
and low- or intermediate-risk features as determined by the
TIMI score. Revascularization in such patients with a
low-risk score was graded as uncertain, meaning that
revascularization may be reasonable, with the caveat that
there is limited data on clinical benefit. For patients with an
intermediate-risk score, revascularization was rated appro-
priate as it was for patients at high risk (Fig. 1).
In the 2009 AUC document, the clinical scenario of an
asymptomatic patient without prior bypass surgery and with 1-
or 2-vessel disease not involving the proximal LAD in whom
no noninvasive testing had been performed was not evaluated
because this clinical scenario was felt to be uncommon.
However, for future mapping of the AUC to the CathPCI
registry, the appropriateness of this clinical scenario was graded
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did not affect the appearance of Figures 2, 3, and 4 below because
hey include indications that were not updated.
PCI and CABG in Patients With Multivessel CAD
In this group of ratings, it is assumed that revascularization is
appropriate, and the technical panel rated the appropriateness of
the mode of revascularization independently for CABG and PCI
(Fig. 5). The writing group and technical panel felt some quan-
tification of CAD burden, either by description or SYNTAX
score, could be helpful to clinicians. CABG was rated as appro-
priate in all of the new clinical scenarios developed, whereas PCI
was rated as appropriate only in patients with 2-vessel CAD with
involvement of the proximal LAD and in patients with 3-vessel
disease with a low CAD burden. PCI for 3-vessel disease with a
high CAD burden, however, was rated as uncertain. PCI for
isolated left main stenosis is now graded as uncertain, as are
scenarios with 3-vessel CAD with intermediate to high CAD
burden and left main stenosis and additional CAD with low
CAD burden. PCI is considered inappropriate for left main
stenosis and additional CAD with intermediate to high CAD
burden.
Clinical Judgment and
Understanding the AUC Ratings
Although the appropriate use ratings reflect a general
assessment of when revascularization may or may not be
useful for specific patient populations, physicians and other
stakeholders should continue to acknowledge the pivotal
role of clinical judgment in determining whether revascu-
larization is indicated for an individual patient. For example,
the rating of a revascularization indication as inappropriate
or uncertain should not preclude a provider from perform-
ing revascularization procedures when there are patient- and
condition-specific data to support that decision. Indeed, this
may reflect optimal clinical care, if supported by mitigating
patient characteristics. Likewise, uncertain indications re-
quire individual physician judgment and understanding of
the patient to better determine the usefulness of revascular-
ization for a particular clinical scenario. The ranking of
uncertain (4 to 6) should not be viewed as excluding the
use of revascularization for such patients. Finally, there
may be clinical scenarios in which the use of coronary
revascularization for an indication considered to be appro-
priate does not always represent reasonable practice, such
that the benefit of the procedure does not outweigh the
risks. Accordingly, the AUC are intended to evaluate overall
patterns of care regarding revascularization rather than
adjudicating specific cases. In situations where there is
substantial variation between the appropriate use rating and
what the clinician believes is the best recommendation for
the patient, further considerations or actions such as a
second opinion may be appropriate. It is not anticipated that
all physicians or facilities will have 100% of their revascu-
larization procedures deemed appropriate. However, related
to the overall patterns of care, if the national average ofappropriate procedure ratings is 80%, e.g., and a physician
or facility has only a 40% rate of appropriate procedures,
further examination of the patterns of care may be war-
ranted and helpful.
Stable Ischemic Heart Disease With Prior CABG
The writing group did not feel the focused update needed to
address any clinical scenarios in patients with stable isch-
emic heart disease and prior CABG. These indications from
the prior document show a pattern similar to that seen in
patients without prior CABG; the presence of high-risk
findings on noninvasive testing, higher severity of symp-
toms, or an increasing burden of disease in either the bypass
grafts or native coronaries increased the likelihood of an
appropriate rating. The only inappropriate ratings in pa-
tients with prior CABG were noted in patients receiving no
or minimal anti-ischemic therapy or having low-risk find-
ings on noninvasive testing. More uncertain ratings oc-
curred in this group of patients, reflecting their higher
complexity, higher risk, and the limited availability of
published evidence regarding management outcome.
Application of Criteria
There are many potential applications for the AUC. Clini-
cians can use the ratings for decision support or as an
educational tool when considering the need for revascular-
ization. Moreover, these criteria can be used to facilitate
discussion with patients and/or referring physicians about
the need for revascularization. Facilities and payers may
choose to use these criteria either prospectively in the design
of protocols or pre-authorization procedures, or retrospec-
tively for quality reports. It is hoped that payers would use
these criteria to ensure that their members receive necessary,
beneficial, and cost-effective cardiovascular care, rather than
for other purposes.
It is expected that services performed for appropriate
indications will receive reimbursement. In contrast, services
performed for inappropriate indications may require addi-
tional documentation to justify payment because of the
unique circumstances or the clinical profile that may exist in
such a patient. This additional documentation should not be
required for uncertain indications. It is critical to emphasize
that the writing group, technical panel, AUC Task Force,
and clinical community do not believe an uncertain rating
justifies denial of reimbursement for revascularization. Rather,
uncertain ratings are those in which the available data vary and
many other factors exist that may affect the decision to perform
or not perform revascularization. The opinions of the technical
panel often varied for these indications, reflecting that addi-
tional research is needed. Indications with high clinical volume
that are rated as uncertain identify important areas for further
research. The AUC writing group and technical panel favor
the collaborative interaction of cardiac surgeons and interven-
tional cardiologists Heart Team approach regarding revascu-
larization decisions in complex patients or coronary anatomy.
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should be used in conjunction with efforts that lead to
quality improvement. Prospective pre-authorization proce-
dures, if put in place, are most effective once a retrospective
review has identified a pattern of potential inappropriate
use. Because these criteria are based on current scientific
evidence and the deliberations of the technical panel, they
should be used prospectively to generate future discussions
about reimbursement, but should not be applied retrospec-
tively to cases completed before issuance of this report or
documentation of centers/providers performing an unex-
pectedly high proportion of inappropriate cases as compared
with their peers.
The writing group recognizes that these criteria will be
evaluated during routine clinical care. To that end, specific
data fields such as symptom status, presence or absence of
acute coronary syndrome, history of bypass surgery, extent
of ischemia on noninvasive imaging, CAD burden, and
degree of antianginal therapy are anticipated to provide
sufficient detail to determine individual appropriate use
ratings. Because a reasonable and tolerated dose of antiangi-
nal therapy may vary significantly among different patients,
the writing group continues to recommend the use of 2
classes of antianginal therapies as a minimum standard for
medical therapy. The writing group also recognizes all data
(e.g., visual assessment of stenosis severity, interpretation of
noninvasive imaging, symptom severity) collected to assess
appropriate use relies on its content accurately reflecting
actual patient characteristics. Any current variability in these
data points need to be addressed before accurate determi-
nation of appropriate use can be provided.
The primary objective of this report is to provide guid-
ance regarding the suitability of coronary revascularization
for diverse clinical scenarios. As with previous AUC docu-
ments, consensus among the technical panel members was
desirable, but an attempt to achieve complete agreement
within this diverse panel would have been artificial and was
not the goal of the process. Two rounds of ratings with
substantial discussion among the technical panel members
between the ratings did lead to some consensus among
panelists. However, further attempts to drive consensus
would have diluted true differences in opinion among
panelists and, therefore, was not undertaken. Moreover,
remarkable concordance between the appropriateness rat-
ings from the original criteria and 85 cardiologists not
participating in the process, and blinded to the initial
results, has been documented (20).
Future research analyzing patient outcomes for indica-
tions rated as appropriate will help ensure the equitable and
efficient allocation of resources for coronary revasculariza-
tion. Review of appropriateness patterns may also improve
understanding of regional variations in the use of revascu-
larization as highlighted in the Dartmouth Atlas Project
(21). Further exploration of the indications rated as uncer-
tain will help generate the information required to further
define the appropriate use of coronary revascularization.Additionally, the criteria will need to be updated with the
publication of ongoing trials in coronary revascularization
and new clinical practice guidelines. For additional infor-
mation and discussion of the literature, please see the
ACCF/AHA PCI and CABG guidelines (12,13).
In conclusion, this document represents the current
understanding of the clinical benefit of coronary revascular-
ization with respect to health outcomes and survival. It is
intended to provide a practical guide to clinicians and
patients when considering revascularization. As with other
AUC, the results of some of these ratings will require
research and further evaluation to provide the greatest
information and benefit to clinical decision making.
Appendix A: Additional Coronary
Revascularization Definitions
Angina/Chest Pain Classification
Angina is a syndrome typically noted to include discomfort
in the chest, jaw, shoulder, back, or arm that is aggravated
by exertion or emotional stress and relieved by nitroglycerin.
The quality of the discomfort, provoking factors, and
relieving factors are used to define typical, atypical, and
noncardiac chest pain. Atypical angina is generally defined
by 2 of the above 3 characteristics, and noncardiac chest
pain is generally defined as chest pain that meets 1 or none
of the above criteria. These definitions are presented below.
Clinical Classification of Chest Pain (22):
• Typical Angina (Definite): Defined as 1) substernal
chest pain or discomfort that is 2) provoked by
exertion or emotional stress and 3) relieved by rest
and/or nitroglycerin.
• Atypical Angina (Probable): Chest pain or discomfort
that lacks 1 of the characteristics of definite or typical
angina.
• Nonanginal Chest Pain: Chest pain or discomfort
that meets 1 or none of the typical angina
characteristics.
The writing group assumes that noninvasive assessments of
coronary anatomy (i.e., cardiac computed tomography, car-
diac magnetic resonance angiography) provide anatomic
information that is potentially similar to x-ray angiography.
However, these modalities do not currently provide infor-
mation on ischemic burden and are not assumed to be
present in the clinical scenarios.
Invasive Methods of Determining
Hemodynamic Significance
The writing group recognizes that not all patients referred
for revascularization will have previous noninvasive testing.
In fact, there are several situations in which patients may be
appropriately referred for coronary angiography based on
symptom presentation and a high pretest probability of
coronary artery disease. In these settings, there may be
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of questionable hemodynamic importance in a patient with
symptoms that can be related to myocardial ischemia. In
such patients, the use of additional invasive measurements
(such as fractional flow reserve or intravascular ultrasound)
at the time of diagnostic angiography may be very helpful in
further defining the need for revascularization and substi-
tuted for stress test findings (Table A2).
Appendix B: Additional Methods
See the earlier Methods section of the report for a descrip-
tion of technical panel selection, indication development,
scope of indications, and rating process.
Relationships With Industry and Other Entities
The American College of Cardiology Foundation and its
partnering organizations rigorously avoid any actual, per-
ceived, or potential conflicts of interest that might arise as a
result of an outside relationship or personal interest of a
member of the technical panel. Specifically, all panelists are
asked to provide disclosure statements of all relationships
that might be perceived as real or potential conflicts of
interest. These statements were reviewed by the AUC Task
Table A2. Noninvasive Risk Stratification
High-risk (3% annual mortality rate)
1. Severe resting left ventricular dysfunction (LVEF 35%)
2. High-risk treadmill score (score 11)
3. Severe exercise left ventricular dysfunction (exercise LVEF 35%)
4. Stress-induced large perfusion defect (particularly if anterior)
5. Stress-induced multiple perfusion defects of moderate size
6. Large, fixed perfusion defect with LV dilation or increased lung uptake
(thallium-201)
7. Stress-induced moderate perfusion defect with LV dilation or increased
lung uptake (thallium-201)
8. Echocardiographic wall motion abnormality (involving 2 segments)
developing at low dose of dobutamine (10 mg/kg/min)
or at a low heart rate (120 beats/min)
9. Stress echocardiographic evidence of extensive ischemia
ntermediate-risk (1% to 3% annual mortality rate)
1. Mild/moderate resting left ventricular dysfunction (LVEF 35% to 49%)
2. Intermediate-risk treadmill score (score between 11 and 5)
3. Stress-induced moderate perfusion defect without LV dilation or increased
lung intake (thallium-201)
4. Limited stress echocardiographic ischemia with a wall motion abnormality
only at higher doses of dobutamine involving less than or equal to
2 segments
Low-risk (1% annual mortality rate)
1. Low-risk treadmill score (score 5)
2. Normal or small myocardial perfusion defect at rest or with stress*
3. Normal stress echocardiographic wall motion or no change of limited
resting wall motion abnormalities during stress*
*Although the published data are limited, patients with these findings will probably not be at low
risk in the presence of either a high-risk treadmill score or severe resting left ventricular
dysfunction (LVEF 35%). Reprinted with permission from Patel et al. (1).
LV  left ventricular; LVEF  left ventricular ejection fraction.Force, discussed with all members of the technical panel atthe face-to-face meeting, and updated and reviewed as
necessary. A table of disclosures by all participants, who are
listed in Appendix C, in the Appropriate Use Criteria for
Coronary Revascularization can be found in Appendix D.
In addition, to ensure complete transparency, complete
disclosure information—including relationships not per-
tinent to this document—is available online as a document
supplement.
Literature Review
The technical panel members were asked to refer to the
relevant guidelines for a summary of the relevant literature,
guideline recommendation tables, and reference lists pro-
vided for each indication table when completing their
ratings (Online Appendix).
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Expert
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Coronary Revascularization Appropriate Use Criteria Writing Group
anesh R. Patel None None None None None None
regory J. Dehmer None None None None None None
ohn W. Hirshfeld ● St. Jude
Medical
None None None None None
Peter K. Smith ● Eli Lilly None None None None None
John A. Spertus ● St. Jude
Medical
None None ● BMS/sanofi-
aventis
partnership†
● Eli Lilly†
None None
Coronary Revascularization Appropriate Use Criteria Technical Panel
Frederick A. Masoudi None None None None None None
Ralph G. Brindis None None None None None None
regory J. Dehmer None None None None None None
anesh R. Patel None None None None None None
eter K. Smith ● Eli Lilly None None None None None
Karen J. Beckman None None None None None None
harles E. Chambers None None None None None None
. Bruce Ferguson None None None None None None
ario J. Garcia None None None None None None
rederick L. Grover None None None None None None
avid R. Holmes Jr. None None None None None None
loyd W. Klein None None None None None None
arian C. Limacher None None None None None None
ichael J. Mack None None None None None None
avid J. Malenka None None None ● St. Jude Medical
Foundation
None None
Myung H. Park
Michael Ragosta III None None None None None None
James L. Ritchie None None None None None None
Geoffrey A. Rose None None None None None None
Alan B. Rosenberg None None ● WellPoint, Inc.† None ● WellPoint, Inc.† None
ndrea M. Russo ● Medtronic
● Sanofi-Aventis
● Boston
Scientific
● Medtronic
● St. Jude
Medical
None ● Medtronic None None
ichard J. Shemin None None None None None None
illiam S. Weintraub None None None None None None
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Institutional,
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Coronary Revascularization Appropriate Use Criteria Indication Reviewers*
tephan Achenbach None None None ● Siemens Medical
Solutions
None None
Joseph S. Alpert None None None None None None
H. Vernon Anderson None ● Bristol-Myers
Squibb
Pharmaceuticals
● Sanofi-aventis
Pharmaceuticals
None None None None
Elliott M. Antman ● Eli Lilly
● Sanofi-aventis
None None ● Bristol-Myers
Squibb
Pharmaceutical
Research
Institute
● Eli Lilly and
Company
● Sanofi-aventis
None None
Lee M. Arcement None None None None None None
R. Morton Bolman None None None None None None
Javed Butler None None None None None None
Jun R. Chiong None None None None None None
G. William Dec None None None None None None
David P. Faxon None None None None None None
Raymond J. Gibbons None None None None None None
Robert A. Guyton ● Medtronic None None None None None
Alice K. Jacobs None None None None None None
ohn A. Kern None None None None None None
loyd W. Klein None None None None None None
ichael J. Mack None None None None None None
. Brent Mitchell ● Medtronic ● Medtronic
Canada
None ● Medtronic
Canada
None None
Marc R. Moon None None None None None None
Douglass A. Morrison None None None None None None
Reid T. Muller None None None None None None
Sherif F. Nagueh ● GE Healthcare
● St. Jude
Medical
● Medtronic None None None None
avin C. Nanda Philips None None None None None
illiam C. Nugent None None None None None None
yung H. Park None None None None None None
ichael Poon None None None None None None
ohn D. Puskas ● Medtronic None None ● Medtronic (royalty
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Rita F. Redberg None None None None None None
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Ownership/
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Principal Research
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Organizational, or
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Benefit
Expert
Witness
Appropriate Use Criteria Task Force
ichael J. Wolk None None None None None None
teven R. Bailey None None None None None None
amela S. Douglas None None None None None None
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This table represents the relevant relationships with industry and other entities that were disclosed by participants at the time of participation. It does not necessarily reflect relationships at the time
of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of
$10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship
is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each
category of review. Participation does not imply endorsement of this document. *Relationships were recorded at the time of review for the 2009 publication. Because the reviewers did not review the
focused update, their information was not updated for this document. †Significant relationship.
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